DAR-901

Dartmouth-Hitchcock Medical Center · Phase 2 active Biologic

At a glance

Generic name	DAR-901
Sponsor	Dartmouth-Hitchcock Medical Center
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

DAR-901 TB Booster Vaccine to Prevent TB in Adolescents (PHASE2)
Phase I Trial of DAR-901 (PHASE1)
Investigational Vaccine for the Prevention of Disseminated Tuberculosis in HIV Infected People (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DAR-901 CI brief — competitive landscape report
DAR-901 updates RSS · CI watch RSS
Dartmouth-Hitchcock Medical Center portfolio CI